Faruqi and Faruqui, LLP Logo
Share this page

NewLink Genetics Corporation (NLNK)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In NewLink Genetics Corporation To Contact The Firm Before Lead Plaintiff Deadline

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in NewLink Genetics Corporation (“NewLink” or the “Company”) (NASDAQ:NLNK) of the July 11, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased or otherwise acquired NewLink securities between September 17, 2013 and May 9, 2016 (the “Class Period”).  The case, Abramson v. NewLink Genetics Corporation et al, No. 1:16-cv-03545 was filed on May 12, 2016, and has been assigned to Judge William H. Pauley III.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failed to disclose that: (i) algenpantucel-L, a pancreatic cancer treatment, was ineffective and potentially dangerous to patients; and (ii) as a result, NewLink’s public statements were materially false and misleading.

Specifically, on May 9, 2016, after market close, NewLink announced that algenpantucel-L did not meet the main goal in the Company’s Phase 3 IMPRESS study. Patients treated with algenpantucel-L lived for a median of 27.3 months in NewLink's Phase 3 trial, compared to median survival of 30.4 months for patients treated with standard therapy, indicating that patients were actually harmed by NewLink's treatment.

On this news, NewLink’s share price fell from $16.50 per share on May 9, 2016 to a closing price of $11.45 on May 10, 2016 —a $5.05 or a ~30.61% drop.

Take Action

If you invested in NewLink stock or options between September 17, 2013 and May 9, 2016 and would like to discuss your legal rights, please fill out the form below or contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding NewLink’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    NewLink Genetics Corporation (NLNK)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 05/17/2016

Class Period:

  • 09/17/2013 - 05/09/2016

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.